Results 91 to 100 of about 4,221,746 (249)

Translating whole‐genome doubling into precision medicine in cancer

Molecular Oncology, EarlyView.
Whole‐genome doubling creates a WGD‐positive tumor state characterized by persistent chromosomal instability, karyotypic diversification, and cellular stress. These same biological pressures drive aggressive tumor evolution while exposing therapeutic vulnerabilities, providing a rationale for WGD‐informed precision medicine. Whole‐genome doubling (WGD)
Sejung Lee, Junghyeok Lim, Jinhyuk Bhin
wiley   +1 more source

Stress‐Programmed Immune Niches Fuel TNFR2+ Treg Activation and Drive Neoadjuvant Chemotherapy Resistance in Breast Cancer

Advanced Science
The tumor microenvironment (TME) harbors diverse immune cell states that shape therapeutic outcomes in breast cancer. Here, we identify a conserved stress‐programmed cellular module as a key responder to neoadjuvant therapies in breast cancer ...
Zhibo Shao, Xuliren Wang, Han Zhu, Ling Yao, Qi Zhang, Zihan Zhai, Xinyi Lv, Xinyuan Xia, Yi Zhang, Xinya Lu, Xinyi Quan, Jiawen Yang, Xinwei Li, Jieyi Dong, Zhi‐ming Shao, Ruoxi Wang, Bingqiu Xiu, Jiong Wu, Sheng Chen   +18 more
doaj   +1 more source

Standardization of multi disciplinary team treatment for breast cancer (2023 edition)

Zhongguo aizheng zazhi, 2023
Breast cancer has become the most common malignant tumor in the world since 2020. With the diagnosis and therapeutic regimens improvement in breast cancer, survival rate of Chinese patients has been significantly enhanced in recent years.
Specialty Construction-Multidisciplinary Expert Committee for Creating Healthy China Energizing, Society of Breast Cancer China Anti-Cancer Association The   +1 more
doaj  

Targeting transcription factors associated with hemoglobinopathies: Lessons from successful interventions and implications for cancer

Molecular Oncology, EarlyView.
This review summarizes the transcription factors, repressive chromatin‐modifying complexes, and epigenetic mechanisms that control fetal hemoglobin repression. Notably, many regulators of γ‐globin silencing also function in transcriptional and epigenetic networks that drive cancer, highlighting opportunities to translate advances in hemoglobinopathy ...
Meigen Yu, Puspa Das, Xing Zhang, Xiaodong Cheng   +3 more
wiley   +1 more source

Pathological response and metabolites’ prognostic role in HER2-positive breast cancer treated with neoadjuvant pyrotinib, trastuzumab, nab-paclitaxel, and carboplatin: a single-arm phase II trial

Breast Cancer Research
Background The trial aimed to evaluate the efficacy and safety of pyrotinib in combination with trastuzumab, nab-paclitaxel, and carboplatin (TCbHPy) in the neoadjuvant setting (ChiCTR2100043523), as well as the role of metabolites in predicting the ...
Mei Liu, La Zou, Ningning Zhang, Wenqi Zhou, Xianjun Pan, Yongchun Deng, Yeli Yue, Jing Wu, Xinrui Liang, Maoshan Chen, Xiaohua Zeng   +10 more
doaj   +1 more source

Pharmacological chromatin remodeling enhances response to estrogen therapy in ER+ breast cancer

Molecular Oncology, EarlyView.
Estrogen therapy elicits clinical benefit in ~ 30% of patients with endocrine‐resistant estrogen receptor (ER)‐positive breast cancer. Based on findings that ER transcriptional activation underlies response to estrogen therapy, we tested the effects of epigenetic dysregulation via pharmacological inhibition of histone deacetylases (HDACi).
Anneka L. Johnson Thomas, Barbara Karakyriakou, Patricia C. Muskus, Alyssa M. Roberts, Justin Rendleman, Alexa Warren, Hanxu Lu, Kimberly A. Birmingham, Malone K. Friedman, Abigail E. Goen, Huijuan Yang, Owen M. Wilkins, Fred W. Kolling, Eugene Demidenko, Julie M. Jorns, Brock C. Christensen, Todd W. Miller   +16 more
wiley   +1 more source

Chidamide combined with fulvestrant in the treatment of HR-positive, HER2-negative advanced breast cancer after failure of previous endocrine therapy: a single-arm, single-center, phase 2 study

Breast Cancer Research
Background Chidamide is an oral subtype-selective histone deacetylase inhibitor that has been used as an anti-cancer agent. This study evaluated the efficacy and safety of chidamide plus fulvestrant in the treatment of HR-positive and HER2-negative ...
La Zou, Xianjun Tang, Pan Deng, Yijing Liu, Ti Yang, Xin Tan, Lu Yang, Wei Li, Xiaohua Zeng   +8 more
doaj   +1 more source

PANoptosis in the pathogenesis of myelodysplastic syndromes

Molecular Oncology, EarlyView.
PANoptosis, a combination of three types of programmed cell death, is mediated by a large protein complex called a PANoptosome. In healthy bone marrow hematopoietic cells, PANoptosis is restricted by inhibitory signaling. In MDS, bone marrow cells become sensitive to the PANoptotic stimuli due to the aberrant inactivation of inhibitory signaling or ...
Rohit Thalla, Jyoti Lamichhane, Cameron Lewis, Peter Breslin, Jiwang Zhang   +4 more
wiley   +1 more source

Docetaxel rechallenge in HER2-negative metastatic breast cancer: a real-world study of previously discontinued patients for non-progression reasons

Journal of Cancer Research and Clinical Oncology
Purpose This study aimed to evaluate the efficacy and safety of docetaxel rechallenge in HER2-negative metastatic breast cancer (MBC) patients who discontinued docetaxel for reasons other than disease progression.
Hui-Ai Zeng, Hui-Min Lv, Meng-Wei Zhang, Li-Min Niu, Jing Wang, Hui-Hui Sun, Zhen-Zhen Liu, Min Yan   +7 more
doaj   +1 more source

Spatial biology in cancer epigenetics

Molecular Oncology, EarlyView.
Spatial epigenomics combines molecular profiling with tissue architecture to reveal how gene regulation is organized within intact tissues. In cancer, these technologies uncover the mechanisms driving tumor heterogeneity and microenvironmental interactions, opening new opportunities for biomarker discovery and precision medicine.
Eva Crespo‐García, Manel Esteller
wiley   +1 more source